Dr. A. Stylianou Unveils Groundbreaking AFM-Based Nanomechanical
Biomarkers at the 29th Congress of the European Society of Biomechanics
Edinburgh, Scotland – July 3, 2024 – Dr. A. Stylianou, leader of the Cancer
Mechanobiology and Applied Biophysics Research Group at the Basic and
Translational Cancer Research Center, delivered an influential perspective talk
titled "AFM-based Nanomechanical Biomarkers" at the 29th Congress of the
European Society of Biomechanics, held from June 30 to July 3, 2024.
In the presentation, Dr. Stylianou highlighted the revolutionary impact of Atomic
Force Microscopy (AFM) in developing novel nanomechanical biomarkers. AFM
stands out as a unique tool, allowing for the precise probing of biological samples
at the nanoscale. This technique provides unprecedented insights into the
mechanical properties of cells and tissues, thereby aiding in the quantification of
these properties with exceptional precision.
"AFM is transforming our approach to biomechanics research by unveiling the
intricate nanoscale mechanical properties of life," said Dr. Stylianou. "The
development of AFM-based nanomechanical biomarkers is paving the way for
innovative solutions in healthcare and beyond."
Recent advances in AFM technology underscore its transformative potential,
emphasizing the need for further exploration in technology enhancement, data
analysis, and collaborative research. These biomarkers are set to reshape our
understanding of biology, offering new avenues for diagnosis and treatment of
various physiological and pathological conditions.
This work was conducted under the project "MechanoLung"
(EXCELLENCE/0421/0263). The project is implemented under the programme of
social cohesion “THALIA 2021-2027” co-funded by the European Union, through
Research and Innovation Foundation.